Advanced Therapies Week
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Advanced Therapies Week — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
Advanced Therapies Week 2027
Date: 18–21 January 2027
Venue: Convention Center, San Diego, USA
Event Type: Cell & Gene Therapy Conference, Biotech, Pharma, Advanced Therapies
Estimated Attendance: 1800+ Attendees (including 600+ Cell & Gene Therapy Developers, 250+ World-Class Speakers, 200+ Exhibitors)
1. Who Attends (BUYERS / ATTENDEES)
Advanced Therapies Week attracts a diverse audience of professionals from the biotech, pharma, academic, and healthcare sectors. Key attendee profiles include:
- Cell & Gene Therapy Developers
- Biotech and Pharmaceutical Company Executives
- Academic Researchers and Institutions
- Investors and Venture Capitalists
- Contract Manufacturing Organizations (CMOs)
- Regulatory Affairs and Compliance Professionals
- Healthcare Providers and Patient Advocacy Groups
- Technology and Service Providers (e.g., CROs, CDMOs, Technology Platforms)
2. Location + Attendee Geographic Origin
Show Location: Convention Center, San Diego, USA
Attendee Origin: Global, with a strong presence from North America, Europe, and Asia. The event draws international participants due to its reputation as a premier biotech partnering event.
Best Geographic Targeting: Global biotech and pharma hubs, including the USA, UK, Germany, Switzerland, Japan, and South Korea.
3. Audience Reach
Reach Type: Global. Advanced Therapies Week is recognized as a leading international event for the cell and gene therapy sector, attracting participants from over 160 countries.
4. Sample Buyer Company Names + Websites
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Moderna Therapeutics | https://www.modernatx.com | Chief Medical Officer, Cell & Gene Therapy | Leading biotech company investing heavily in mRNA and gene therapy research. |
| 2 | Roche Pharmaceuticals | https://www.roche.com | Head of Cell & Gene Therapy Development | Global pharmaceutical leader with a dedicated cell and gene therapy division. |
| 3 | Lonza Group | https://www.lonza.com | Business Development Manager, Cell & Gene Therapy | Key CMO providing manufacturing services for advanced therapies. |
| 4 | Thermo Fisher Scientific | https://www.thermofisher.com | Director, Cell & Gene Therapy Solutions | Major supplier of technologies and services for cell and gene therapy production. |
| 5 | Bluebird Bio | https://www.bluebird.bio | VP, Global Therapeutic Area Head, Cell Therapy | Pioneer in gene therapy with multiple approved products and a robust pipeline. |
| 6 | Sanofi Genzyme | https://www.sanofi.com | Head of Cell & Gene Therapy, R&D | Pharmaceutical company with a strong focus on rare diseases and gene therapy. |
| 7 | CRISPR Therapeutics | https://www.crisprtherapeutics.com | Chief Scientific Officer, Cell Therapy | Leader in gene-editing technology with several cell therapy candidates in development. |
| 8 | Vectrus, Inc. | https://www.vectrus.com | Director, Life Sciences & Advanced Therapies | Provides solutions for advanced therapy manufacturing and logistics. |
| 9 | Global Stem Cell Group | https://www.globalstemcellgroup.org | CEO, Stem Cell Research & Development | Organization focused on stem cell and regenerative medicine research and applications. |
| 10 | Oxford BioMedica | https://www.oxfordbiomedica.com | Chief Operating Officer, Gene Therapy | Biotech company specializing in gene therapy and viral vector production. |
| 11 | Horizon Discovery Group | https://www.horizondiscovery.com | VP, Cell & Gene Therapy Research Services | Provides tools and services for gene editing and cell therapy research. |
| 12 | Thermo Fisher Scientific (Life Sciences) | https://www.thermofisher.com | Senior Marketing Manager, Cell & Gene Therapy | Offers a wide range of products for cell and gene therapy development and manufacturing. |
| 13 | Lonza Group (Cell & Gene Therapy Division) | https://www.lonza.com | Head of Cell & Gene Therapy Business Development | Leading CMO with specialized services for advanced therapy manufacturing. |
| 14 | Stanford University - Cell Therapy | https://celltherapy.stanford.edu | Director, Cell Therapy Research | Prominent academic institution conducting cutting-edge cell therapy research. |
| 15 | Harvard Stem Cell Institute | https://stemcells.harvard.edu | Executive Director, Stem Cell Research | Leading research institute in stem cell biology and regenerative medicine. |
| 16 | Novartis Cell & Gene Therapy | https://www.novartis.com | Head of Cell & Gene Therapy, R&D | Pharmaceutical giant with a dedicated cell and gene therapy division and approved therapies. |
| 17 | GSK Cell & Gene Therapy | https://www.gsk.com | VP, Cell & Gene Therapy Development | Global pharmaceutical company investing in gene therapy for rare diseases. |
| 18 | Amgen Cell Therapy | https://www.amgen.com | Director, Cell Therapy Research & Development | Biotech leader exploring cell therapy applications for various diseases. |
| 19 | Regeneron Genetics Center | https://www.regeneron.com | Head of Gene Therapy Research | Pharmaceutical company with a strong focus on genetics and gene therapy development. |
| 20 | University of Pennsylvania - Gene Therapy Program | https://gene-therapy.upenn.edu | Director, Gene Therapy Research | Pioneering academic institution in gene therapy research and clinical applications. |
5. Job Profiles, Industries & Event Type
Best Job Profiles to Target:
- Cell & Gene Therapy Developers
- Biotech Executives (CEO, CTO, CSO)
- Pharmaceutical R&D Leaders
- Contract Manufacturing Organization (CMO) Executives
- Investment and Venture Capital Professionals
- Academic Researchers and Professors
- Regulatory Affairs and Compliance Officers
- Healthcare and Patient Advocacy Leaders
- Technology and Service Providers (e.g., CROs, CDMOs, Platform Providers)
Best Industries to Target (Based on Apollo Industry List):
- Biotechnology
- Pharmaceuticals
- Healthcare
- Medical Research
- Contract Manufacturing
- Life Sciences
- Academic Research
- Investment Banking
- Healthcare Services
Event Type: Cell & Gene Therapy Conference, Biotech, Pharma, Advanced Therapies, Networking, Innovation, Investment
6. Estimated Attendance
Expected Total Footfall: 1800+ Attendees
- 600+ Cell & Gene Therapy Developers
- 250+ World-Class Speakers
- 200+ Advanced Therapies Exhibitors
7. Key Focus Areas & Buyer Engagement
Key Focus Areas:
- Cell & Gene Therapy Development
- Advanced Therapies Manufacturing
- Regulatory and Compliance Challenges
- Investment and Funding Opportunities
- Partnership and Collaboration Opportunities
- Patient Access and Advocacy
- Innovation in Therapeutic Development
Buyer Engagement Angle: Position the event as a premier platform for connecting with key decision-makers in the cell and gene therapy space, including developers, manufacturers, investors, and academic researchers. Highlight opportunities for collaboration, investment, and staying updated on the latest industry advancements.
8. Client-Product Fit Note
Please share your client's website to finalize the exact buyer list. The right buyers depend heavily on the client's product or service. Examples:
- If the client sells cell & gene therapy research tools, target companies like Moderna, CRISPR Therapeutics, and academic research institutions.
- If the client offers contract manufacturing services, focus on CMOs like Lonza and pharmaceutical companies with outsourcing needs.
- If the client provides gene editing technologies, target biotech firms and research organizations involved in gene therapy development.
- If the client is in healthcare or patient advocacy, engage with patient advocacy groups, healthcare providers, and regulatory bodies.
9. Final Recommendation
Advanced Therapies Week 2027 is an excellent event for attendee list sales, particularly for companies in the biotech, pharma, and advanced therapies sectors. The event offers a unique opportunity to connect with a global audience of decision-makers. Quality rating for B2B attendee list sales: 9/10. Strong event with a high concentration of key buyers, extensive networking opportunities, and a proven track record of facilitating partnerships and collaborations.
Data sheet
Advanced Therapies Week – Event Attendee & Buyer Profile Analysis
Event date: 18–21 January 2027
Location: Convention Center, San Diego, California, United States
Event status: Upcoming
Research date: 30 June 2026
Event Overview
| Event Name | Advanced Therapies Week |
| Event Date | 18–21 January 2027 |
| Event Status | Upcoming |
| Venue | Convention Center, San Diego |
| City | San Diego |
| State / Region | California |
| Country | United States |
| Organizer | Phacilitate |
| Official Event Website | phacilitate.com/advanced-therapies-week |
| Event Type | Cell & Gene Therapy Conference and Partnering Event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology; Business Services |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | Historical organizer evidence indicates 1,800+ attendees, 600+ cell & gene therapy developers, 250+ speakers, and 200+ exhibitors. Current 2027 attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Historical / prior-year style organizer website metrics; not confirmed as final 2027 counts. |
| Main Purpose of Event | To connect cell and gene therapy developers, biopharma leaders, investors, manufacturing and technology partners, researchers, and commercialization stakeholders for partnering, sourcing, education, and market development. |
About the Event
Advanced Therapies Week is a U.S.-based cell and gene therapy conference organized by Phacilitate and scheduled to return to San Diego on 18–21 January 2027. The official event site positions it as a leading forum for the advanced therapies ecosystem, bringing together research, therapeutic development, advanced manufacturing, commercialization, and partnering stakeholders.
The event matters because it sits at the intersection of science, clinical translation, manufacturing scale-up, regulation, investment, and commercial readiness. For exhibitors and solution providers, it offers access to a concentrated audience of therapy developers, pharma and biotech executives, translational medicine teams, CDMO/CRO stakeholders, investors, and healthcare institutions evaluating technologies, services, partnerships, and outsourcing options.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Cell & Gene Therapy Developers | Biotech developers, therapy innovators, translational medicine teams | Core buyers of manufacturing, analytics, platform, regulatory, and commercialization services | Highest-value target segment for vendors selling to CGT development and scale-up teams |
| Biopharma Executives | Pharma companies, advanced therapies business units, strategic partnerships teams | Budget owners, alliance leaders, portfolio and external innovation decision-makers | Important for enterprise partnerships, licensing, outsourcing, and strategic procurement |
| Manufacturing, CMC and Tech Ops Leaders | Biotech, biopharma, CDMO, process development and manufacturing organizations | Influence supplier selection for equipment, process tech, QA/QC, supply chain, and scale-up | Critical buyers for manufacturing services, automation, software, and lab infrastructure |
| Regulatory and Quality Leaders | Regulatory affairs, quality assurance, compliance, validation teams | Strong influence on vendor qualification, risk review, and implementation timelines | Relevant to compliance, documentation, testing, and audit-ready service providers |
| Clinical and Translational Leaders | Clinical development groups, hospitals, academic medical centers, translational institutes | Influence adoption of trial support, patient logistics, digital tools, and translational platforms | Relevant to trial operations, patient engagement, biomarker, and data-management suppliers |
| Investors and Venture Capital | VC firms, private investors, strategic investment arms | Influence funding, partnerships, market validation, and portfolio introductions | Useful for ecosystem credibility, strategic introductions, and commercial visibility |
| Contract Service Partners | CDMOs, CROs, specialist service firms, testing and logistics providers | Can act as both sellers and buyers of enabling technologies and subcontracted services | Relevant for channel partnerships, subcontracting, and integration opportunities |
| Healthcare and Academic Institutions | Hospitals, clinics, universities, academic research organizations | Clinical adoption, research collaboration, and translational procurement influence | Valuable for pilot projects, collaborations, and institutional buying cycles |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| San Diego | Confirmed host city; strong likely attendance from local biotech and life sciences ecosystem | High | San Diego is a major U.S. biotech hub with strong relevance for CGT developers, research institutes, and service firms. |
| California | Likely attendee pull from San Francisco Bay Area, Los Angeles, Orange County, and San Diego | Very High | Large concentration of biotech, research, venture, and manufacturing stakeholders. |
| West Coast U.S. | Likely regional attendance from Washington, Oregon, Arizona, and neighboring markets | Medium to High | Convenient access supports regional buyer and partner participation. |
| United States National | Likely strong attendance from Boston/Cambridge, Philadelphia, New Jersey, North Carolina, Maryland, Texas and Midwest biotech clusters | Very High | Official site describes the event as a premier biotech partnering event in the United States. |
| Europe | Likely attendance from UK, Germany, Switzerland, France, and other advanced therapy markets | Medium | Phacilitate states 160+ countries represented across its broader global community; event likely benefits from that international network. |
| Asia and Middle East | Likely international participation from Japan, South Korea, Singapore, and Gulf-region life sciences stakeholders | Medium | International appeal is likely due to cross-border investment, manufacturing, and commercialization themes. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The organizer operates an international advanced therapies platform and states 160+ countries represented across its wider community. Advanced Therapies Week is positioned as a major U.S. partnering event with meaningful international appeal. |
| National | Secondary reach | The official site explicitly describes it as a premier biotech partnering event in the United States, indicating strong nationwide buyer and attendee pull. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Mayo Clinic | Healthcare / research institution | Major translational medicine and clinical institution relevant to advanced therapy development, trials, and adoption. | mayoclinic.org | Director Translational Medicine, Clinical Research Director, Cell Therapy Program Lead | Confirmed Speaker Organization |
| Deerfield Management | Investor / life sciences investment firm | Relevant for investment, strategic introductions, and partnering in cell and gene therapy. | deerfield.com | Partner, Principal, Investment Director, Portfolio Operations Lead | Confirmed Speaker Organization |
| CellServe LLC | Cell therapy services / industry operator | Relevant buyer and ecosystem participant in cell therapy operations and commercialization support. | cell-serve.com | CEO, Commercial Director, Operations Director, Partnerships Lead | Confirmed Speaker Organization |
| Apertura Gene Therapy | Therapy developer | Direct fit for platform, manufacturing, regulatory, analytics, and commercialization suppliers. | aperturagtx.com | CEO, Head of CMC, VP Manufacturing, Director Regulatory Affairs | Confirmed Speaker Organization |
| Lafana Life Sciences | Life sciences company / commercialization stakeholder | Relevant to market access, global ecosystem building, and advanced therapies commercialization. | lafanalifesciences.com | Commercialization Director, BD Director, Market Access Lead, Strategy Lead | Confirmed Speaker Organization |
| NKILT Therapeutics Inc. | Therapy developer | Potential buyer of development, manufacturing, regulatory, and partnering services. | nkilt.com | President, CEO, Head of R&D, CMC Lead | Confirmed Speaker Organization |
| WMC | Industry advisory / consulting | Relevant for strategic consulting, commercialization planning, and ecosystem influence. | Website domain not verified from source text | Principal, Managing Director, Commercial Strategy Lead | Confirmed Speaker Organization |
| Bullpen | Industry organization / advisory brand | Relevant for ecosystem visibility and strategic relationships within advanced therapies. | Website domain not verified from source text | Founder, Principal, Partnerships Lead | Confirmed Speaker Organization |
| Phacilitate | Organizer / industry platform | Relevant for sponsorship, event partnerships, attendee ecosystem access, and sector visibility. | phacilitate.com | Sponsorship Director, Partnerships Director, Event Sales Lead | Confirmed Event Organizer |
Note: The official page provided includes only a limited set of named organizations. A full current-year buyer list was not publicly visible in the source text supplied. The table above therefore focuses on organizations explicitly referenced on the official site.
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Scientific Officer | R&D / Scientific Leadership | C-Level | Influences platform strategy, external collaborations, and innovation priorities. |
| 2 | Chief Technical Officer | Technical Operations | C-Level | Key for process technology, manufacturing systems, and technical partnerships. |
| 3 | VP / Head of Manufacturing | Manufacturing / CMC | VP / Head | Core buyer for equipment, process development, CDMO support, and manufacturing scale-up. |
| 4 | Director of CMC | CMC | Director | Drives technical evaluation of manufacturing, analytics, and quality vendors. |
| 5 | Director of Regulatory Affairs | Regulatory | Director | Important for compliance-driven purchasing and implementation approval. |
| 6 | Quality Assurance Director | Quality | Director | Influences vendor qualification, audit readiness, and quality systems purchases. |
| 7 | Strategic Sourcing Manager | Procurement / Supply Chain | Manager | Relevant where therapy developers are scaling external vendor networks. |
| 8 | Director of Supply Chain | Supply Chain | Director | Important for cold chain, material sourcing, and logistics-intensive therapy operations. |
| 9 | Business Development Director | Business Development | Director | Key for partnerships, licensing, collaborations, and outsourcing arrangements. |
| 10 | Commercialization Lead | Commercial / Market Access | Director / Head | Relevant for launch planning, patient access, and commercialization solutions. |
| 11 | Clinical Operations Director | Clinical Operations | Director | Influences trial services, patient logistics, and data collection vendors. |
| 12 | Principal / Investment Director | Investment | Senior | Useful for strategic introductions, funding visibility, and portfolio partnerships. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core audience for cell and gene therapy development | Therapy developers, platform buyers, scientific leadership |
| 2 | Pharmaceuticals | Large pharma and specialty biopharma participation is highly likely | Partnering, licensing, manufacturing, commercial readiness |
| 3 | Research | Academic and translational research institutions are relevant attendees | Collaboration, translational studies, innovation scouting |
| 4 | Hospital & Health Care | Clinical institutions and patient delivery stakeholders matter in therapy adoption | Clinical operations, treatment center readiness, patient pathways |
| 5 | Medical Devices | Relevant for device-enabled manufacturing, handling, and treatment workflows | Instrumentation, delivery systems, lab/clinical technologies |
| 6 | Information Technology & Services | Digital infrastructure supports data, manufacturing, and trial workflows | Clinical data, manufacturing systems, traceability, workflow tools |
| 7 | Computer Software | Relevant for specialized life sciences software platforms and analytics tools | LIMS, eQMS, manufacturing execution, trial data platforms |
| 8 | Logistics & Supply Chain | Advanced therapies require specialized logistics and chain-of-custody support | Cold chain, patient sample handling, transport visibility |
| 9 | Management Consulting | Commercialization, regulatory, and strategy advisors are relevant in this market | Go-to-market, operations scaling, partnership strategy |
| 10 | Venture Capital & Private Equity | Investment summit and funding themes make investor participation relevant | Investor outreach, portfolio partnerships, strategic growth |
| 11 | Higher Education | Universities and academic research centers contribute to translational pipelines | Research collaboration and innovation transfer |
| 12 | Events Services | Useful when targeting sponsors, organizers, and ecosystem connectors | Sponsorship and partnership development |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 1,800+ | Historical / prior-year evidence | Official event homepage metrics | Not confirmed as the final 2027 attendee count. |
| Cell & gene therapy developers | 600+ | Historical / prior-year evidence | Official event homepage metrics | Useful indicator of buyer concentration. |
| Speaker count | 250+ | Historical / prior-year evidence | Official event homepage metrics | Indicates strong thought-leadership and executive participation. |
| Exhibitor count | 200+ | Historical / prior-year evidence | Official event homepage metrics | Confirms substantial supplier presence. |
| Buyer count | Not publicly confirmed | Unconfirmed | No buyer-specific count visible in supplied official text | Developer count is the strongest proxy for buyer-side presence. |
| Sponsor count | Not publicly confirmed in supplied text | Unconfirmed | Official page references 2026 sponsors but no count included in supplied extract | Potentially verifiable from sponsor directory on the official site. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Cell & Gene Therapy Development | R&D acceleration, process development, translational support | Meet therapy developers and scientific leaders early in the decision cycle | Research tools, platform technologies, assay services, development consulting |
| Advanced Manufacturing | Scale-up, process control, automation, quality systems | High-value discussions with CMC, manufacturing and tech ops leaders | Equipment, CDMO services, software, QC/QA tools, automation platforms |
| Commercialization | Market access, launch planning, pricing, patient pathways | Engage commercial and market access leaders preparing for launch | Commercial strategy, patient services, data platforms, access support |
| Regulatory & Compliance | Documentation, quality, validation, audit readiness | Relevant for trust-based consultative sales with regulatory stakeholders | Regulatory consulting, eQMS, validation services, compliance software |
| Investment & Partnering | Funding access, strategic alliances, portfolio visibility | Useful for investor relations, strategic BD, and co-development opportunities | Advisory services, diligence support, partnering platforms |
| Clinical Translation | Trial execution, patient logistics, treatment center coordination | Opportunity to reach hospitals, clinics, and clinical ops teams | Clinical services, scheduling, logistics, digital trial support |
| Data & Digital Platforms | Traceability, analytics, workflow integration, interoperability | Good fit for software vendors serving regulated life sciences workflows | LIMS, MES, supply chain tracking, analytics, cloud data solutions |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event directly serves therapy developers, biopharma leaders, and advanced manufacturing stakeholders. |
| Decision-maker availability | High | Official site highlights executive, scientific, and commercialization participation. |
| Data collection potential | Medium | Useful for list building and sponsor targeting, but publicly visible named attendee data appears limited in the supplied source text. |
| Apollo targeting potential | Very High | Advanced therapies maps well to Apollo filters across biotech, pharma, research, healthcare, software, and supply chain sectors. |
| Geographic targeting potential | High | Strong concentration in U.S. biotech hubs with additional global reach. |
| Best outreach approach | High-touch, insight-led outreach | Use event relevance, manufacturing/commercialization pain points, and partnership value propositions rather than generic sales messaging. |
| Overall lead quality | Very High | Excellent fit for B2B life sciences vendors, specialist service providers, and technology suppliers. |
| Best use case | ABM, executive outreach, partnership development, exhibitor targeting | Most effective when combined with role-based Apollo targeting and event-context personalization. |
| Limitations / risks | Medium | Current-year named attendee transparency is limited in the supplied materials; buyers and exhibitors should not be conflated without direct evidence. |
B2B attendee list building suitability: Good for account-based targeting and named-organization prospecting, but current-year public buyer-list visibility appears limited based on the supplied official content.
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Research; Hospital & Health Care; Medical Devices; Information Technology & Services; Computer Software; Logistics & Supply Chain; Management Consulting; Venture Capital & Private Equity | Covers the core advanced therapies ecosystem and adjacent buying influencers. |
| Departments | Research, Operations, Manufacturing, Quality Assurance, Regulatory Affairs, Supply Chain, Business Development, Clinical, IT, Executive | Targets the functions most involved in vendor evaluation and partnership decisions. |
| Seniority | C-Level, VP, Head, Director, Senior Manager, Partner, Principal | Focuses on strategic and budget-holding stakeholders. |
| Job titles | Chief Scientific Officer, Chief Technical Officer, Head of Manufacturing, VP Manufacturing, Director CMC, Director Regulatory Affairs, QA Director, Supply Chain Director, Strategic Sourcing Manager, Clinical Operations Director, Business Development Director, Commercialization Lead, Cell Therapy Program Director | High-fit contacts for advanced therapies buying cycles. |
| Geography | United States first; California, Massachusetts, Pennsylvania, New Jersey, Maryland, North Carolina, Texas; secondary markets in UK, Switzerland, Germany, Japan, South Korea, Singapore | Captures core U.S. biotech hubs plus likely international attendee bases. |
| Employee size | 11–50; 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Covers venture-backed developers through major biopharma and health systems. |
| Keywords | cell therapy, gene therapy, CGT, advanced therapies, CMC, viral vector, regenerative medicine, autologous, allogeneic, translational medicine, GMP, ATMP, CAR-T, manufacturing scale-up | Improves precision for niche advanced therapies accounts and contacts. |
| Technologies | If relevant to client offering: LIMS, MES, QMS, cloud data platforms, clinical software, cold-chain/logistics tools | Useful when the client sells software or digital infrastructure. |
| Revenue range | Use open range; segment separately for pre-commercial biotechs and enterprise pharma | Revenue alone is less reliable in biotech; use alongside employee size and funding profile. |
| Company type | Public and Private; nonprofit hospitals and academic institutions where relevant | Expands coverage across commercial and institutional buyers. |
| Funding / public company filters | Recently funded biotech companies; publicly listed biopharma; portfolio-backed therapeutics developers | Helpful for prioritizing active spenders and scale-stage companies. |
Suggested Apollo Search Logic: ("cell therapy" OR "gene therapy" OR CGT OR "advanced therapies" OR "regenerative medicine" OR CAR-T OR ATMP) AND (manufacturing OR CMC OR regulatory OR commercialization OR clinical OR supply chain) with seniority filters set to Director+ and geography weighted to U.S. biotech hubs first, then international CGT clusters.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| Advanced Therapies Week Official Event Page | Official event website | Confirmed event name, official dates, host city, country, venue wording, return statement for 2027, historical attendance metrics, event positioning, and named participant organizations shown on the page. | Very High |
| Phacilitate Official Website | Organizer website | Verified organizer identity, broader community scale, international footprint, and positioning within the cell and gene therapy market. | Very High |
| Official page references: “2026 Registered Attendee List,” “2026 Sponsors,” “2026 Agenda at a Glance,” “2026 Wrap-Up” | Official linked resources referenced on event page | These references support the existence of deeper attendee and sponsor materials, but their underlying contents were not included in the supplied source text. Therefore no unsupported participant claims were made from them. | High |
| Verification note | Research control note | The user-supplied start/end dates conflicted with the official page. This report follows the official website, which states 18–21 January 2027 in San Diego, USA. | Very High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Advanced Therapies Week — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds